Phathom Pharmaceuticals, Inc.

  • Safety Score
  • Market Cap $417.75M
  • Debt $175.73M
  • Cash $334.68M
  • EV $258.80M
  • FCF -$247.72M

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings-$339.45M
EBIT-$287.93M
ROA-74%
FCF-$247.72M
Equity-$187.11M
Growth Stability1
PE-1.23
PB-2.23
P/FCF-1.69
P/S15.9
Price/Cash0.8
Debt/Equity-0.94
Debt/FCF-0.71
Net Margins-1K%
Gross Margins84%
Op. Margins-1K%
Sales Growth QoQ123%
Sales CAGR1%
Equity CAGR-3%
Earnings Growth YoY98%
Earnings Growth QoQ-6%
Sales CAGR 5Y2%
Equity CAGR 5Y-7%
Earnings CAGR 3Y29%
Sales CAGR 3Y29%
Market Cap$417.75M
Revenue$26.27M
Assets$387.04M
Total Debt$175.73M
Cash$334.68M
Shares Outstanding60.54M
EV258.8M
Safety Score35%
Working Capital308.53M
Current Ratio5.73
Gross Profit$21.95M
Shares Growth 3y26%
Equity Growth QoQ-20%
Equity Growth YoY953%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

SEC Filings

Direct access to Phathom Pharmaceuticals, Inc. (PHAT) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2024
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2022
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Phathom Pharmaceuticals, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Phathom Pharmaceuticals, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Phathom Pharmaceuticals, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Phathom Pharmaceuticals, Inc..

= -$2.5B
012345678910TV
fcf-$248M-$248M-$248M-$248M-$248M-$248M-$248M-$248M-$248M-$248M-$248M-$2.5B
DCF-$225M-$205M-$186M-$169M-$154M-$140M-$127M-$116M-$105M-$96M-$955M
Value-$2.5B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12/201812/201912/202012/202112/202212/2023TTM
Net Margins------30K%-1K%
ROA--41%-43%-71%-105%-40%-74%
ROE--112%-66%-199%264%277%-

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12/201812/201912/202012/202112/202212/2023TTM
Debt over FCF---0.81-0.67-0.68-1.01-0.71
Debt over Equity-1.520.110.31.39-1.34-1.92-0.94
Growth Stability------1

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12/201812/201912/202012/202112/202212/2023CAGR 5Y
Revenue YoY growth------2%
Earnings YoY growth-20K%-49%11%37%2%-
Equity YoY growth--18K%-15%-63%-204%-3%-7%
FCF YoY growth--93%111%-1%-6%-